As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7 will remove the geographic shackles and place the products with the partner best-suited to maximize their growth worldwide.
Patisiran and fitusiran are the most advanced molecules in the 2014 collaboration to co-develop and co-commercialize rare disease RNAi therapeutics discovered by Alnylam. Under the restructured deal, Alnylam gained worldwide rights to patisiran, an IV RNAi therapeutic targeting the transthyretin (TTR) gene using second-generation lipid nanoparticle (LNP) technology, and its follow-on molecule ALN-TTRsc02. Sanofi gained worldwide rights to fitusiran, which